ING Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.6M | Sell |
364,984
-73,282
| -17% | -$3.98M | 0.08% | 197 |
|
|
2026
Q1 | $27.5M | Buy |
438,266
+292,042
| +200% | +$23.4M | 0.17% | 104 |
|
|
2025
Q4 | $13.9M | Sell |
146,224
-101,072
| -41% | -$9.91M | 0.08% | 159 |
|
|
2025
Q3 | $24.1M | Buy |
+247,296
| New | +$25.6M | 0.13% | 112 |
|
|
2025
Q2 | – | Sell |
-210,992
| Closed | -$21.3M | – | 486 |
|
|
2025
Q1 | $21.3M | Buy |
210,992
+22,753
| +12% | +$2.29M | 0.15% | 107 |
|
|
2024
Q4 | $16.8M | Sell |
188,239
-8,711
| -4% | -$767K | 0.11% | 139 |
|
|
2024
Q3 | $16.5M | Sell |
196,950
-881
| -0.4% | -$69.4K | 0.1% | 150 |
|
|
2024
Q2 | $15.2M | Sell |
197,831
-33,215
| -14% | -$2.43M | 0.09% | 160 |
|
|
2024
Q1 | $15.8M | Buy |
231,046
+167,091
| +261% | +$10.7M | 0.11% | 165 |
|
|
2023
Q4 | $3.7M | Sell |
63,955
-119,865
| -65% | -$6.4M | 0.03% | 337 |
|
|
2023
Q3 | $9.71M | Sell |
183,820
-103,901
| -36% | -$5.45M | 0.09% | 201 |
|
|
2023
Q2 | $15.6M | Buy |
287,721
+163,029
| +131% | +$8.51M | 0.12% | 143 |
|
|
2023
Q1 | $6.24M | Sell |
124,692
-115,623
| -48% | -$5.45M | 0.06% | 224 |
|
|
2022
Q4 | $11.1M | Buy |
240,315
+15,937
| +7% | +$690K | 0.11% | 143 |
|
|
2022
Q3 | $8.69M | Sell |
224,378
-46,577
| -17% | -$1.87M | 0.15% | 120 |
|
|
2022
Q2 | $10.1M | Buy |
270,955
+44,873
| +20% | +$1.83M | 0.12% | 141 |
|
|
2022
Q1 | $10M | Buy |
226,082
+39,124
| +21% | +$1.7M | 0.1% | 155 |
|
|
2021
Q4 | $7.94M | Buy |
186,958
+65,739
| +54% | +$2.76M | 0.07% | 211 |
|
|
2021
Q3 | $5.26M | Buy |
121,219
+2,558
| +2% | +$113K | 0.07% | 190 |
|
|
2021
Q2 | $5.07M | Buy |
118,661
+22,870
| +24% | +$962K | 0.08% | 160 |
|
|
2021
Q1 | $3.7M | Buy |
95,791
+813
| +0.9% | +$30.8K | 0.08% | 160 |
|
|
2020
Q4 | $3.41M | Buy |
94,978
+63,315
| +200% | +$2.28M | 0.08% | 171 |
|
|
2020
Q3 | $1.21M | Buy |
31,663
+19,579
| +162% | +$754K | 0.05% | 177 |
|
|
2020
Q2 | $424K | Sell |
12,084
-13,414
| -53% | -$483K | 0.02% | 196 |
|
|
2020
Q1 | $832K | Sell |
25,498
-9,007
| -26% | -$352K | 0.04% | 204 |
|
|
2019
Q4 | $1.56M | Sell |
34,505
-52,430
| -60% | -$2.19M | 0.05% | 237 |
|
|
2019
Q3 | $3.54M | Buy |
+86,935
| New | +$3.68M | 0.09% | 152 |
|
|
2019
Q2 | – | Sell |
-206,425
| Closed | -$7.92M | – | 762 |
|
|
2019
Q1 | $7.92M | Buy |
206,425
+200,648
| +3,473% | +$7.66M | 0.17% | 86 |
|
|
2018
Q4 | $204K | Sell |
5,777
-185,298
| -97% | -$6.72M | ﹤0.01% | 660 |
|
|
2018
Q3 | $7.36M | Buy |
+191,075
| New | +$6.67M | 0.13% | 119 |
|
|
2018
Q2 | – | Sell |
-140,480
| Closed | -$3.84M | – | 739 |
|
|
2018
Q1 | $3.84M | Buy |
140,480
+109,914
| +360% | +$2.99M | 0.07% | 154 |
|
|
2017
Q4 | $758K | Sell |
30,566
-17,848
| -37% | -$492K | 0.01% | 394 |
|
|
2017
Q3 | $1.41M | Sell |
48,414
-148,774
| -75% | -$4.11M | 0.03% | 263 |
|
|
2017
Q2 | $5.47M | Buy |
197,188
+188,736
| +2,233% | +$5.01M | 0.1% | 119 |
|
|
2017
Q1 | $210K | Sell |
8,452
-105,133
| -93% | -$2.56M | ﹤0.01% | 541 |
|
|
2016
Q4 | $2.46M | Buy |
+113,585
| New | +$2.48M | 0.05% | 196 |
|
|
2016
Q1 | – | Sell |
-16,563
| Closed | -$306K | – | 556 |
|
|
2015
Q4 | $306K | Buy |
+16,563
| New | +$297K | ﹤0.01% | 603 |
|
|
2015
Q2 | – | Sell |
-361,440
| Closed | -$6.42M | – | 627 |
|
|
2015
Q1 | $6.42M | Buy |
361,440
+309,150
| +591% | +$4.89M | 0.03% | 351 |
|
|
2014
Q4 | $693K | Buy |
+52,290
| New | +$668K | ﹤0.01% | 627 |
|
Other funds holding BSX
ING Group's BSX Position: Q2 2026 in Review
ING Group reduced its Boston Scientific (BSX) stake by 17% in Q2 2026, selling an estimated $3.98M and leaving 364,984 shares worth $15.6M. The position accounts for 0.08% of the portfolio, ranked #197.
ING Group first reported a position in BSX in Q4 2014 and has held it in 39 quarters since. The position peaked at $27.5M in Q1 2026. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- ING Group held 364,984 shares of Boston Scientific worth $15.6M as of Q2 2026.
- ING Group sold 73,282 Boston Scientific shares in Q2 2026, an estimated $3.98M.
- Boston Scientific made up 0.08% of ING Group's portfolio in Q2 2026, its #197 holding.
- ING Group first reported a position in Boston Scientific in Q4 2014 and has held it in 39 quarters since.
- ING Group's Boston Scientific position peaked at $27.5M in Q1 2026.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.